Patents Assigned to Merck
  • SURFACE, ANCHORED FC-BAIT ANTIBODY DISPLAY SYSTEM
    Publication number: 20180002402
    Abstract: The present invention provides, in part, an antibody display system that simultaneously uses a secretion and a display mode. A bait complexed with a monovalent antibody fragment can be expressed on the surface of the host cell wherein the fragment may be assayed for antigen binding while full antibody is simultaneously secreted from the host cell. Methods of using the system for identifying antibodies that bind specifically to an antigen of interest are also provided. Polypeptides, polynucleotides and host cells useful for making the antibody display system are also provided along with methods of use thereof.
    Type: Application
    Filed: May 25, 2016
    Publication date: January 4, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dongxing Zha, Hussam Hisham Shaheen
  • Materials for electronic devices
    Patent number: 9859502
    Abstract: The invention relates to compounds according to formula (1), said compounds being suitable for use in electronic devices, in particular in organic electroluminescent devices.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: January 2, 2018
    Assignee: Merck Patent GmbH
    Inventors: Arne Buesing, Irina Martynova, Frank Voges, Jonas Valentin Kroeber
  • Eu-activated luminophores
    Patent number: 9856417
    Abstract: The invention relates to Eu2+-activated phosphors, to a process for the preparation of these compounds, and to phosphor mixtures, light sources and lighting units which comprise the Eu2+-activated phosphors according to the invention.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: January 2, 2018
    Assignee: Merck Patent GmbH
    Inventors: Ralf Petry, Holger Winkler, Tim Vosgroene, Christof Hampel, Andreas Benker, Thomas Juestel
  • Triazolo[4,5-d]pyrimidine derivatives
    Patent number: 9855268
    Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: January 2, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Guenter Hoelzemann, Michel Calderini, Ansgar Wegener, Oliver Poeschke
  • LIQUID CRYSTALLINE MEDIUM
    Publication number: 20170369781
    Abstract: The present invention relates to a liquid-crystalline medium based on a mixture of polar compounds having negative dielectric anisotropy (??), which is distinguished by the fact that it has a value for the ratio ?1/?n2 in the range 6-45 with a clearing point of >60° C. and a ?? of ??2.3. Media of this type are particularly suitable for electro-optical displays having active-matrix addressing based on the ECB, PA LCD, FFS or IPS effect.
    Type: Application
    Filed: August 15, 2017
    Publication date: December 28, 2017
    Applicant: Merck Patent GmbH
    Inventors: Melanie KLASEN-MEMMER, Sabine SCHOEN
  • NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES
    Publication number: 20170369507
    Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Application
    Filed: December 1, 2015
    Publication date: December 28, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Fischer Christian, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, Michael J. Ellis, Sara Esposite, Qingmei Hong, Chunhui Huang, Alexander J. Kim, John W. Lampe, Michelle R. Machacek, Daniel R. McMasters, Ryan D. Otte, Dann L. Parker, Jr., Michael H. Reutershan, Nunzio Sciammetta, Patrick Pengcheng Shao, David L. Sloman, Feroze Ujjainwalla, Catherine White, Zhicai Wu, Yang Yu, Kake Zhao, Craig R. Gibeau
  • IMINOTHIADIAZINE DIOXIDES BEARING AN AMINE-LINKED SUBSTITUENT AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE
    Publication number: 20170369484
    Abstract: In its many embodiments, the present invention provides certain iminothiazine dioxide compounds, including compounds Formula (I): or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, ring A, RA, m, ring B, RB, and n are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: January 15, 2016
    Publication date: December 28, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Shuwen He, Shawn P. Walsh, Jared N. Cumming
  • THIADIAZOLYL - OXIMINOACETIC ACID DERIVATIVE COMPOUNDS
    Publication number: 20170369459
    Abstract: Thiadiazolyl-oximinoacetic acid derivatives have been synthesized, which are useful in the manufacture of cephalosporin antibiotic compounds. Compound (1) (TATD) is commercially available (CAS No. 76028-96-1). It has now been discovered that the thiadiazolyl-oximinoacetic acid derivative compound (1) (TATD) can be prepared from dimethyl malonate (SM 1, CAS No. 108-59-8) according to methods described herein. The methods provide products having desirable purity.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 28, 2017
    Applicant: Merck Sharp & Dohme Corpl
    Inventors: Kristos Adrian Moshos, Valdas Jurkauskas
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20170369469
    Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 28, 2017
    Applicants: Cerecor, Inc., Merck Sharp & Dohme Corp.
    Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
  • BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA
    Publication number: 20170369780
    Abstract: The invention relates to bimesogenic compounds of formula I to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.
    Type: Application
    Filed: October 23, 2015
    Publication date: December 28, 2017
    Applicant: Merck Patent GmbH
    Inventors: Kevin ADLEM, Owain Llyr PARRI, Rachel TUFFIN, Hassan ARASI, Thomas MACGREGOR
  • METHOD FOR DOPING SEMICONDUCTORS
    Publication number: 20170372903
    Abstract: The present invention relates to a process for the production of structured, highly efficient solar cells and of photovoltaic elements which have regions of different doping. The invention likewise relates to the solar cells having increased efficiency produced in this way.
    Type: Application
    Filed: December 1, 2015
    Publication date: December 28, 2017
    Applicant: MERCK PATENT GMBH
    Inventors: Oliver DOLL, Ingo KOEHLER, Sebastian BARTH
  • TRICYCLIC GYRASE INHIBITORS
    Publication number: 20170369498
    Abstract: Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.
    Type: Application
    Filed: July 7, 2017
    Publication date: December 28, 2017
    Applicants: Merck Sharp & Dohme Corp., LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
    Inventors: Daniel Bensen, Zhiyong Chen, John Finn, Thanh T. Lam, Suk J. Lee, Xiaoming Li, Douglas W. Phillipson, Leslie W. Tari, Michael Trzoss, Junhu Zhang, Felice C. Lightstone, Toan B. Nguyen, Sergio E. Wong, Paul Aristoff, Michael Jung
  • BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA
    Publication number: 20170369784
    Abstract: The invention relates to bimesogenic compounds of formula I wherein R11, R12, MG11, MG12 and CG1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.
    Type: Application
    Filed: December 2, 2015
    Publication date: December 28, 2017
    Applicant: MERCK PATENT GMBH
    Inventor: David WILKES
  • SOLID DISPERSION FORMULATIONS OF ANTIVIRAL COMPOUNDS
    Publication number: 20170368031
    Abstract: The present disclosure is directed to solid dispersion formulations comprising an NS5A inhibitor compound, elbasvir (dimethyl N,N?-([(6S)-6-phenylindolo [1,2- c][1,3]benzoxazine-3,10-diyl]bis {1H-imidazole-5,2-diyl-(2S)-pyrrolidine-2,1-diyl[(2S)-3-methyl-l-oxobutane-1,2-diyl]})di-carbamate), or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable polymer, and optionally a pharmaceutically acceptable surfactant. The present disclosure is also directed to solid dispersion formulations, blended compositions and pharmaceutical dosage forms containing or made from these solid dispersion formulations, and the methods for making these solid dispersion formulations, blended compositions and pharmaceutical dosage forms.
    Type: Application
    Filed: November 6, 2015
    Publication date: December 28, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Agam SHETH, Pavithra SUNDARARAJAN, Elise MILLER, Justin David MOSER, Adam J SOCIA, Angela M WAGNER
  • OPTICAL SWITCHING DEVICE
    Publication number: 20170371186
    Abstract: An optical switching device comprising a polarisation layer and a switching layer which comprises a liquid-crystalline material and a dye compound. Use of the optical switching device for the regulation of the passage of light through an area element. A window element which has the optical switching device therein.
    Type: Application
    Filed: June 21, 2017
    Publication date: December 28, 2017
    Applicant: Merck Patent GmbH
    Inventors: Michael JUNGE, Andreas BEYER, Mila FISCHER
  • Heterocyclic derivatives as modulators of kinase activity
    Patent number: 9850255
    Abstract: The invention provides novel imidazol-piperidinyl derivatives of the formula (I) in which R1, R2, W, X1, X2, X3, X4 and n have the meanings indicated in formula I, and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: December 26, 2017
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Bayard R. Huck, Xiaoling Chen, Yufang Xiao
  • Process for making CGRP receptor antagonists
    Patent number: 9850246
    Abstract: The invention encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, which are CGRP receptor antagonists useful for the treatment of migraine.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: December 26, 2017
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Frank Chen, Carmela Molinaro, W. Peter Wuelfing, Nobuyoshi Yasuda, Jianguo Yin, Yong-Li Zhong, Joseph Lynch, Teresa Andreani
  • Metal complexes
    Patent number: 9853228
    Abstract: The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, comprising these metal complexes.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: December 26, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Nils Koenen, Philipp Stoessel, Anna Hayer, Holger Heil, Philipp Harbach
  • Transparent, electrically semiconducting interference TiOpigments with high color strength
    Patent number: 9850384
    Abstract: The present invention relates to transparent, electrically semiconducting interference pigments having high color strength, and in particular to flake-form interference pigments which comprise an oxygen-deficient layer of TiO2-x, to a process for the preparation of such pigments, and to the use of the pigments prepared in this way.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: December 26, 2017
    Assignee: MERCK PATENT GMBH
    Inventor: Reinhold Rueger
  • Inhibitors of the renal outer medullary potassium channel
    Patent number: 9850245
    Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: December 26, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Alexander Pasternak, Fa-Xiang Ding, Shuzhi Dong, Jinlong Jiang, Haifeng Tang, Xin Gu, Reynalda K. DeJesus, Jessica Frie, Qinghong Fu, Takao Suzuki, Zhifa Pu